PrintBio
Developing 3D-bioprinted living implants and resorbable surgical meshes to repair or replace damaged human tissues.
- CEO / Founder
- Kevin Slawin, MD
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $31.4M
- Latest Round
- Series A
- Key Investors
- Rapha Capital Management, Expa, Blue Collective, Aurum Venture Partners, Network VC
Technology & Products
Key Products
3D-bioprinted living implants, resorbable surgical meshes, hernia division
Technological Advantage
Proprietary end-to-end biofabrication pipeline including GMPrint™ and Uniflex™ technology.
Differentiation
Value Proposition
Bio-compatible, resorbable tissue solutions that integrate naturally with the body.
How They Differentiate
FDA-cleared resorbable meshes that facilitate natural tissue regeneration.
Market & Competition
Target Customers
Surgeons, hospitals, federal health agencies
Industry Verticals
["Biotechnology","Regenerative Medicine","Medical Devices"]
Competitors
Aspect Biosystems, Cyfuse, Allevi
Growth & Milestones
Growth Metrics
Commercial stage with FDA clearances.
Major Milestones
["FDA 510(k) clearance for 3DMatrix™ (2022)","ARPA-H PRINT program selection (2024)"]
Notable Customers
ARPA-H; WFIRM (federal consortium partners)